Tango ( TNGX ) Q2 Revenue Drops 52%
Tango Therapeutics ( NASDAQ:TNGX ) , a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025. The highlight of the release was a steep decline in GAAP revenue, well below consensus, along with a larger net loss compared to analyst ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q2 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
- First patient dosed in combination trial of TNG462 and Revolution Medicines RAS ( ON ) inhibitors ...
IGM Biosciences, Inc. ( IGMS ) Q2 Earnings and Revenues Surpass Estimates
IGM Biosciences (IGMS) delivered earnings and revenue surprises of +626.67% and +4,388.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. ( MIRM ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Tango Therapeutics ( TNGX ) Could Rally 61.46%: Here's is How to Trade
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 61.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics, Inc. ( TNGX ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Tango Therapeutics (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, July 22, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. TNGX, today announced that it will report second quarter 2025 financial results on August 5, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Does Tango Therapeutics ( TNGX ) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?
The mean of analysts' price targets for Tango Therapeutics (TNGX) points to a 75.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and ...
Tango Therapeutics ( TNGX ) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Gold Royalty ( AMEX:GROY ) , IonQ ( NYSE:IONQ )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 150 points on Monday. Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure ...
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday - AeroVironment ( NASDAQ:AVAV ) , Applied Digital ( NASDAQ:APLD )
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Friday. Shares of Quanex Building Products Corporation NX rose sharply during Friday's session after the company reported better-than-expected second-quarter financial results.
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
BOSTON, May 27, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare ...
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
BOSTON, May 21, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q1 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -5.88% and 13.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
- Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected ...
Beam Therapeutics Inc. ( BEAM ) Reports Q1 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -11.71% and 51.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. ( TNGX ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
BOSTON, May 01, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps. top-line data expected in the second half of ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -9.38% and 47.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Prothena ( PRTA ) Reports Q4 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of -5.88% and 85.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences ( EXAS ) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 81.25% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc.
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
BOSTON, Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive ...
Tango Therapeutics, Inc. ( TNGX ) Reports Q3 Loss, Tops Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 20.59% and 44.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. ( TNGX ) Reports Q2 Loss, Tops Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 29.41% and 169.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amgen ( AMGN ) Expected to Beat Earnings Estimates: Should You Buy?
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Tango Therapeutics, Inc. ( TNGX ) Q2 Earnings Expected to Decline
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics ( TNGX ) Surges 6.7%: Is This an Indication of Further Gains?
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
NEW YORK and VIENNA, July 22, 2024 ( GLOBE NEWSWIRE ) -- HOOKIPA Pharma Inc. ( NASDAQ: HOOK ) ( "HOOKIPA" or the "Company" ) , a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as ...
Tango Therapeutics ( TNGX ) Moves 10.3% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - Tango Therapeutics ( NASDAQ:TNGX )
On Thursday, Tango Therapeutics Inc. TNGX announced that it will discontinue the development of its TNG348 program.
Tango Therapeutics, Inc. ( TNGX ) Reports Q1 Loss, Misses Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of -12.90% and 9.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Tango Therapeutics, Inc. ( TNGX ) Report Negative Q1 Earnings? What You Should Know
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics, Inc. ( TNGX ) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -14.29% and 30.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
MeiraGTx Holdings PLC ( MGTX ) Reports Q4 Loss, Misses Revenue Estimates
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research ( AACR ) Annual Meeting 2024 - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, March 05, 2024 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc.
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research ( AACR ) Annual Meeting 2024
BOSTON, March 05, 2024 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that one abstract has been selected for an oral minisymposium ...
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, Jan. 31, 2024 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc.
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
BOSTON, Jan. 31, 2024 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive ...
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BOSTON, Mass., Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc. ( NASDAQ: TNGX ) , a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective January 2, 2024, the Compensation ...
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, Mass., Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc.
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. ( TNGX ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 110.5% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
How Much Upside is Left in Tango Therapeutics, Inc. ( TNGX ) ? Wall Street Analysts Think 115.31%
The consensus price target hints at an 115.3% upside potential for Tango Therapeutics, Inc. (TNGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology ( SNO ) 28th Annual Meeting
- Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers ...
Tango Therapeutics to Present at the Jefferies London Healthcare Conference - Tango Therapeutics ( NASDAQ:TNGX )
BOSTON, Nov. 07, 2023 ( GLOBE NEWSWIRE ) -- Tango Therapeutics, Inc.
IDEAYA Biosciences, Inc. ( IDYA ) Surges 7.6%: Is This an Indication of Further Gains?
IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
